Creso Pharma Limited Pipeline of launches
Pipeline of launches: Creso Pharma Limited (ASX: CPH) reported that they are on track to launch their CannaQix human health nutraceutical product in anxiety and stress segment by first quarter or second quarter of 2018. They are also aiming and line extensions in bone metabolism by second quarter of 2019. The products use proprietary Swiss delivery technologies which would boost the bioavailability and absorption of their active ingredients. In May, importation of medicinal cannabis in Australia happened while the first patients are currently getting CanniMed oils via Creso’s partner, Health House International. Creso Pharma is targeting to import medical cannabis products into the Asia-Pacific and Latin American regions from Switzerland, post their deal with Cannapharm AG. Meanwhile, Creso Pharma is aiming to launch several SwissVit premium nutraceutical products across the Asia-Pacific region and Australia. These premium, high-quality nutraceutical products are collaborated with INNutriGEL Switzerland using the INNutriGEL SoftGums proprietary delivery technology that was specifically formulated for that range. SoftGums are made from vegetable starch, and not animal waste material like current gelatinbased vitamin competitor supplements on the market.
To read the complete report CLICK HERE. To get your free report CLICK HERE
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.